Human-correlated genetic models identify precision therapy for liver cancer.

ABSTRACT: Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is a leading cause of cancer-related mortality worldwide^1,2. HCC occurs typically from a background of chronic liver disease, caused by a spectrum of predisposing conditions. Tumour development is driven by the expansion of clones that accumulate progressive driver mutations³, with hepatocytes the most likely cell of origin². However, the landscape of driver mutations in HCC is broadly independent of the underlying aetiologies⁴. Despite an increasing range of systemic treatment options for advanced HCC, outcomes remain heterogeneous and typically poor. Emerging data suggest that drug efficacies depend on disease aetiology and genetic alterations^5,6. Exploring

SUBMITTER: Muller M 

PROVIDER: S-EPMC11922762 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature